The use of the medications Wegovy, Ozempic, and Zepbound has skyrocketed as people turn to GLP-1 medications to treat diabetes and obesity
Set up in 1987 in San Diego, Amylin was a small biotechnology company already developing another diabetic drug and agreed to take the gamble with Raufman and Eng's peptide
The study population was identified in the Danish Civil Registration system using the unique personal identification number (CPR), ensuring precise linkage of recorded individual-level information across registers [21]
By binding to GLP-1 receptors in the body, they enhance insulin secretion, suppress glucagon release (another hormone that raises blood sugar), slow gastric emptying, and help regulate appetite and weight
GLP-1 receptor agonists, like Ozempic, work by mimicking a hormone that helps your body release its own insulin, prevents the liver from excess glucose production, and slows the rate at which food leaves the stomach, allowing you to feel fuller longer
Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
